Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINEPSAN extended prednisone maintenance in ANCA-associated vasculitis
2024-514156-33-00Phase 3Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) comparing Extended prednisone maintenance with Placebo comparator (2 arms). Primary endpoint: Relapse-free survival at Month 30. Planned start Jun 2024; status: authorised.
02
Drugs
prednisone
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2024-514156-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514156-33-00.